Glucosidase alfa ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 256 | Muscle glycogenosis | 1 |
256. Muscle glycogenosis
Clinical trials : 180 / Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02824068 (ClinicalTrials.gov) | June 1, 2016 | 20/6/2016 | Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study) | Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months | Pompe Disease | Drug: glucosidase alfa | Klinikum der Universitaet Muenchen | Genzyme, a Sanofi Company | Completed | 8 Years | N/A | All | 112 | Germany;Italy;Taiwan;Argentina;Brazil |